Optimizing Combination Therapies with Existing and Future CML Drugs by Katouli, Allen A. & Komarova, Natalia L.
Optimizing Combination Therapies with Existing and
Future CML Drugs
Allen A. Katouli, Natalia L. Komarova*
Department of Mathematics, University of California Irvine, Irvine, California, United States of America
Abstract
Small-molecule inhibitors imatinib, dasatinib and nilotinib have been developed to treat Chromic Myeloid Leukemia (CML).
The existence of a triple-cross-resistant mutation, T315I, has been a challenging problem, which can be overcome by finding
new inhibitors. Many new compounds active against T315I mutants are now at different stages of development. In this
paper we develop an algorithm which can weigh different combination treatment protocols according to their cross-
resistance properties, and find the protocols with the highest probability of treatment success. This algorithm also takes into
account drug toxicity by minimizing the number of drugs used, and their concentration. Although our methodology is
based on a stochastic model of CML microevolution, the algorithm itself does not require measurements of any parameters
(such as mutation rates, or division/death rates of cells), and can be used by medical professionals without a mathematical
background. For illustration, we apply this algorithm to the mutation data obtained in [1,2].
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Introduction
Chronic Myeloid Leukemia (CML) is a cancer of the white
blood cells. It is characterized by the increased growth of
predominantly myeloid cells in the bone marrow and the
accumulation of these cells in the blood. The disease is associated
with the Philadelphia chromosome, which arises by a reciprocal
translocation between chromosomes 9 and 22 and harbors the
BCR-ABL fusion oncogene [3–6]. The disease mostly affects
adults, and its annual incidence is 1–2 per 100,000 people [7]; the
only well-described risk factor for CML is exposure to ionizing
radiation [8].
Small molecules that specifically target the BCR-ABL gene
product provide a successful treatment approach which can lead to
a reduction of BCR-ABL+ cells below detectable levels, at least
during the early stages of the disease. The drug Imatinib has been
mostly used in this respect [6–11]. It is the first member of a new
class of agents that act by specifically inhibiting a certain enzyme
that is characteristic of a particular cancer cell, rather than non-
specifically inhibiting and killing all rapidly dividing cells. Imatinib
has a number of side-effects, but in general is reasonably well-
tolerated [9], compared to traditional chemotherapeutic agents,
and it has not been found mutagenic [10].
As the disease advances, the chances of treatment failure rise
due to the presence of drug resistant mutants that are generated
mostly through point mutations [11–16]. Drug resistance can
potentially be overcome by the combination of multiple drugs, as
long as a mutation that confers resistance against one drug does
not confer resistance against any of the other drugs in use. In
addition to Imatinib, the drugs Dasatinib and Nilotinib are
alternative inhibitors of the BCR-ABL gene product. Unfortu-
nately, these three drugs exhibit a degree of cross-resistance
because of one mutation (T315I) which confers resistance against
all those drugs [1,17–19]. In addition, there are more than 50
mutations that confer resistance against only one or two of the
three drugs and not against the others [20].
Much research has recently been devoted to understanding the
mechanisms of drug resistance in CML. Drugs in different
combinations and different concentrations have been used in in
vitro experiments to uncover the principles of resistance [21–26]
and to suggest ways to avoid it. It has been suggested that using
several drugs simultaneously, in a combination treatment, rather
than sequentially, will improve the chance of treatment success by
minimizing drug resistance [1,27]. A promising goal is to come up
with different inhibitors [28], and specifically, with agents that are
effective against T315I mutants [2,29–35].
In this paper we will formulate a mathematical model that
allows for a systematic study of drug resistance in cancer and its
effects on treatment. The model will utilize experimental data on
the types of mutants that arise in the context of different
treatments. The goal of this approach is to aid in optimal
treatment strategy design. Our main result is a simple and intuitive
algorithm of finding the optimal combination treatment which (1)
minimizes the chances of treatment failure due to drug resistance,
and (2) minimizes the number and concentration of the drugs
used.
The basic mathematical model used here belongs to the
tradition of stochastic modeling first created by [36–40] and
continued by [41–43]. It is part of the larger effort to model
anticancer therapies in general, and drug resistance in cancer
specifically [44–58]. The approach developed in the present paper
builds on our previous work, where we studied the stochastic
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treatments [59], and created a framework to describe the
phenomenon of cross-resistance [60]. Our goal is to make
stochastic modeling of resistance in CML more relevant for
practicing oncologists by helping them in making the best
treatment protocol choices. To this end, we shift the emphasis
from trying to calculate the probability of treatment success to a
more practical issue of finding the combination of drugs that
maximizes the chances of a successful treatment outcome. In this
paper, we adapt the model to utilize experimental data by
including information on different drug concentrations. Papers
[1,2] suggest that different concentrations of the three available
drugs, imatinib, dasatinib, and nilotinib, can result in the
outgrowth of different numbers of mutations. This means that
resistance generation depends not only on the treatment
composition, but also on the dosages of the various drugs. These
data inspired us to revisit our modeling of combination treatments
with a different approach.
We show that the probability of treatment success is (up to two
significant digits) defined by the cross-resistant mutations. If the
drugs in use possess a degree of triple cross-resistance (such as
imatinib, dasatinib and nilotinib with the T315I mutation), then
the presence of other mutations does not really alter the outcome.
In general, the mutations which confer resistance to the largest
number of drugs in the combination are the ones which define
how likely it is that the protocol fails. Based on this concept, we
developed a counting strategy which can weigh different treatment
strategies according to their cross-resistance properties, and find
the protocols with the highest probability of treatment success.
This algorithm also takes into account drug toxicity by minimizing
the number of drugs used, and their concentration. One useful
feature of this algorithm is that it does not require measurements
of any parameters (such as mutation rates, or division/death rates
of cells), but relies entirely on the knowledge of the number and
resistance types of mutants associated with each of the drugs in
use.
The rest of this paper is organized as follows. First, we
summarize and analyze the biological data which we use in our
scheme. We then describe our analysis of the data, and calculate
the number of mutations resistant to all possible combination
treatments according to the number of drugs, their types and
concentrations. We then present two algorithms to identify the
best possible combination treatments. Finally, we apply both
algorithms to the drugs studied in [1,2] to find the best treatment
strategies.
Materials and Methods
In in vitro experiments described in papers [1,2], CML cancer
cells, Ba/F3 p210
bcr-able were exposed to a minimally cytotoxic
agent, N-ethyl-N-nitrosourea (ENU), a potent inducer of point
mutations. The cells were then cultured in 96-well plates
supplemented with graded concentrations of inhibitors. After
some time (about 28 days), wells with positive outgrows were
expanded and then sequenced for mutations.
In [1], three different inhibitors, imatinib, dasatinib, and
nilotinib, were used, in different combinations and solo. Inhibitor
concentrations used for the three inhibitors are listed in Table 1.
The noted concentrations were motivated by the fact that nilotinib
is at least 20-fold and dasatinib at least 300-fold more potent than
imatinib [1]. After analysis of the total of 768 wells, there were 726
mutations. Out of the 30 specific point-mutations that had been
identified in imatinib resistant patients, 25 were recovered in this
experiment. In total, 26 point-mutations were identified.
In [2], an inhibitor of the T315I mutant SGX70393 was used
both solo and in combination with the three inhibitors, imatinib,
dasatinib and nilotinib. 27 different point-mutations were
identified, 17 of which were novel in comparison to the ones
recovered in [1].
Stochastic modeling
In vitro experiments suggest that different concentrations of a
drug give rise to different numbers and types of resistant mutants
in treating CML. We will model this phenomenon by using an
extension of the stochastic model for combination treatments with
cross-resistance, first introduced in [59,60]. The details of the
model are presented in Text S1, Section 1, and here we only give a
conceptual description.
Stochastic dynamics occurs on a mutation diagram which
specifies the mutation processes that create phenotypes resistant to
various drugs, see figure 1. This network’s nodes denote cancer cell
phenotypes which have different characteristics with respect to
their drug susceptibility. For example, if two drugs are used to treat
the tumor, then potentially there could be at least four different
cell types: those that are fully susceptible; we characterize those by
the binary index s=00; those resistant to drug 1 and susceptible to
drug 2 (s=10); those resistant to drug 2 and susceptible to drug 1
(s=01), and those resistant to both drugs (or, fully-resistant), with
s=11. In general, if m drugs are applied in the course of the
therapy, we have 2
m combinatorial resistance types. The binary
index s has m positions corresponding to the m drugs; ‘‘1’’ in a
given position denotes resistance to the corresponding drug, while
‘‘0’’ means susceptibility.
The nodes of the network are connected with arrows
corresponding to mutation processes which transform one cell
type into another. The mutation rates are marked by the arrows
and denote the probability to produce one daughter cell of the
transformed type upon a division of the cell of the given type. We
neglect the back-mutations because they only provide a small
correction to the processes governed by the forward mutations, see
[61] and Section 2 in Text S1.
The dynamics of cells include the following events: a faithful cell
division (such that both daughter cells are of the original type), a
division with a mutation, and cell death (other events such as
cellular quiescence and awakening from the state of quiescence
could also be included, see [62,63]). A division with a mutation
implies that one of the daughter cells acquires a different
phenotype, in agreement with the mutation network, while the
other daughter cell does not carry the mutation. A simultaneous
generation of two mutant cells (with mutations of a type relevant to
the processes of interest) is possible, but it is a rare event compared
to the production of only one mutant daughter cell, and will be
neglected here.
Table 1. Categorization of the doses of each inhibitor.
Low Dose (nM) Medium Dose(nM) High Dose(nM)
Imatinib 2000 4000–8000 16000
Dasatinib 5 10–25 100–500
Nilotinib 50–250 500–1000 2000–5000
SGX70393 120–240 480–960 1920
The drug concentrations that were used in [1,2] are all included in this table. We
define our dose or concentration for each inhibitor (rows) through the doses
used (columns).
doi:10.1371/journal.pone.0012300.t001
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death rate of cells (that is, their death rate in the absence of
treatment), and the drug-induced death rate. To model the latter
quantity, we ask: how do individual drug-induced death rates of
several drugs interact under combination treatment conditions? In
particular, what is the combined drug-induced death rate of two
drugs applied in combination? On one extreme, it could be the
same as the killing rate of the stronger of the drugs, which would
mean that adding a weaker drug does not change the rate at which
susceptible cells are killed. On the other extreme we have a sum of
the two killing rates, which means that all drugs contribute
proportionally to the killing rate. In the general case of m drugs, we
assume that the effect of the drug combination on cell types
susceptible to all the drugs is somewhere between the maximum
(individual) killing rate and the sum of all the killing rates (see text
S1 for the exact formulation).
At time t=0, we assume that a cancerous colony starts growing
stochastically from M0 susceptible cells; at the time when
treatment begins, there are N cells in the colony; this includes
both susceptible cells and cells of other types generated before
treatment starts. A stochastic model based on the processes
described above has been formulated and analyzed in [59,64]. In
this paper we will move a step forward in terms of biological
realism and design a way to incorporate the existing experimental
data on BCR-ABL mutations into the model. One approach
would be to list all the different molecular types (that is, take
account of all the genotypes that appear in the experimental data)
and keep track of whether they are resistant or susceptible to each
of the drugs at each concentration. Consequently, there would be
as many nodes in the network as there are different mutants.
Furthermore, for each drug combination/concentration, different
nodes would be subject to different drug-induced death rates. In
particular, a given node can be susceptible for some drug
combinations, and resistant for others.
However, here we adopt a different approach. We fix a simple
combinatorial mutation network whose nodes have binary indices,
as described above. These nodes correspond to different resistance
phenotypes rather than genotypes. Depending on the drug
combinations/concentrations that are used, the molecular types
that comprise each phenotype will change. In order to capture the
effect of drug concentration we note that as a result of an increase
in a drug concentration, the relevant resistance classes will contain
fewer mutants. In this model we assume that the total mutation
rate between classes i and j is proportional to the number of
different point mutations that transform a cell from class i to class j.
Therefore, a decrease in a number of types comprising a resistance
class will result in a decrease in the mutation rates generating this
class. For example, an increase in the concentration of drug 1 (see
figure 1) will reduce the resistance classes 100, 101, 110 and 111,
and therefore the rates u1, u12, u13 and u123 will be reduced.
Classification of mutations
We will use the following convention for mutation rates:
uk~iku,
where u is the rate of point mutations per cell division per base-
pair, and ik is the number of point mutations conferring resistance
to the k
th drug. For cross-resistance we use the same notation,
using subscripts to indicate the particular drug numbers that the
mutant is resistant to; for example, the number of mutations that
confer resistance to drugs 1 and 3 is denoted by i13. We will utilize
the experimental data from papers [1,2] in order to calculate the
quantities is, isk and iskm. To this end, we develop some basic rules
for data analysis.
We divide the concentrations of each drug into three categories:
low dose, medium dose, and high dose; Table 1 describes these
categories for each drug. From this convention, we can use the
data to extract the types of point-mutations resistant to each drug,
according to their category of concentrations. Table 2 lists all the
mutation types found in the experiments and specifies if they are
resistant to different drugs. This table indicates if a mutant is
resistant to each concentration of each drug; this is marked by a
‘‘+’’. If the mutant is susceptible to the concentration of a drug,
then there are no markings in the table. In constructing table 2, we
took the convention that if a mutation was found at a certain
category, say medium dose, then we add this mutant to all lower
categories, even if this was not found in the data (due to certain
random fluctuations involved in any experimental procedures).
The rationale behind this is as follows: if there was outgrowth of a
particular mutant in presence of a drug with some concentration,
then it is likely that this mutant can grow in any lower
concentration of that drug.
We use the data for combinations of inhibitors from both papers
to identify mutants that were present in the different concentra-
tions of the drugs in treatment. If a mutation is present in a
combination of two drugs, then that mutant is resistant to each
drug. For example, the mutant L248K was not recovered for solo
treatments for imatinib or SGX70393. However, in combination
this mutant did arise. Thus, we assume that this mutant confers
resistance to both imatinib and SGX70393 individually according
to their concentrations.
The data in Table 2 allows us to determine the number of
resistant and cross-resistant mutants in the context of combining
drugs at different concentrations. Among all the relevant
mutations (that is, all the mutations that give rise to resistant
phenotypes) in the context of combination treatments, we will
distinguish three types:
1. Singly-resistant mutations, that is, mutations that confer
resistance to only one drug (the number of mutations giving
rise to resistance to drug s is denoted by the is count).
2. Doubly-resistant mutations, that is, mutations that confer
resistance to any two drugs (the isk count).
Figure 1. A mutation network for a three-drug treatment. The
nodes correspond to different resistance phenotypes, and the arrows to
mutation processes; mutation rates are marked next to the arrows.
Singly-resistant mutations are denoted my solid lines, doubly-resistant
mutations – by dashed lines and italic font, and the triply-resistant
mutation by a thick line and bold font.
doi:10.1371/journal.pone.0012300.g001
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I/L I/M I/H N/L N/M N/H D/L D/M D/H S/L* S/M* S/H
M244V +
L248R ++ + + + + + +
L248V ++ + +
G250E ++ + + + + +
Q252H ++ + + + + +
Y253H + ++++ + +
E255K + +++ + + +
E255V ++ + + + + + +
D276G +
E292V +
V299L ++
F311I + +
F311V +
T315I + ++++ +++ +
F317C ++ + +
F317I ++ + + + +
F317L ++ + + +
F317V ++ + + +
M351T +
E355G +
F359C ++
F359V +
V379I +
L384M ++
L387F +
H396R ++
G250W +
Y253F ++ ++ +
Y253N + ++
G249D ++
Q252E +
Q252H ++ ++
Y253C + +
L248M ++
L248Q ++ ++
F317S ++
E258K +
G250V ++
N322K +
E355G +
S417Y +
L248K ++ ++ +
G250A + ++
*This indicates that this drug at this concentration cannot kill the un-mutated Native (or wild-type) cell.
The rows define the particular point-mutations and the columns define the inhibitors imatinib (I), nilotinib (N), dasatinib (D), and SGX70393 (S), with the indicated
concentration (L, M, and H for Low, Medium and High, respectively). A ‘‘+’’ indicates that the mutant is resistant.
doi:10.1371/journal.pone.0012300.t002
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resistance to three drugs simultaneously (the iskm count).
The values is, isk, and iskm are calculated from the experimental
data described above, and are presented in Text S1, Section 2 and
Tables 1, 2.1–2.4 and 3.1–3.8.
The stochastic model implemented here will be used for
validating the counting algorithms designed in the next sections.
All the parameters and their definitions are summarized in a table
in Section 1 of Text S1. The parameter value ranges used in the
simulations are as follows: the point mutation rate, u,i s
10{8{10{7 per cell division per base-pair, the cancerous
population size at the beginning of treatment, N,i su pt o1013
[65], the initial colony size M0~10, the death rate to division rate
ratio is between 0 and 0.9, and the drug-induced death rate to
division rate ratio is between 1 and 10.
Results
The stochastic model described here allows one to calculate the
probability of treatment success, given the values of relevant
parameters (such as the division and death of cells, mutation rates,
etc). The problem is that at this moment we do not have reliable
measurements of all the parameters available. Therefore, instead
of attempting to attach a numerical value to the probability of
treatment success, we will design an algorithm which allows us to
select the best drug combination which maximizes the chances of
successful treatment, while keeping the number and concentration
of drugs as low as possible. It turns out that this is possible to
accomplish without the knowledge of the parameters, but only
based on the mutation information on various drugs at different
concentrations. The algorithm is based on some fundamental
properties of mutations which are described next.
Mutation types and their influence on treatment success
In a three-drug treatment, there are three types of mutations
(figure 1): singly- resistant mutations (the i1, i2, and i3 counts),
doubly- resistant mutations (i12, i13, and i23 counts), and triply-
resistant mutations (the i123 count). In order to see how much each
type of mutations affects the probability of treatment success, we
will turn ‘‘on’’ some of these mutations, while leaving the rest of
them ‘‘off’’. Numerical simulations (see the stochastic model of
Text S1) show that triply-resistant mutations have a large influence
on the probability of treatment success, whereas doubly- and
singly-resistant mutations only give corrections to that probability
of the order of 0.1% or less. In table 3, we show an example of this
behavior by comparing the probability of treatment success in the
presence and in the absence of singly- and doubly-resistant
mutations. For singly-resistant mutations, we usei1~i2~i3~30,
which is the maximum count that appears in Text S1, table 1.
Similarly, for doubly-resistant mutants, we take i12~i13~i23~20
(compare to the values in tables 2.1–2.4 of Text S1). Finally, we let
i123~1, and compute the probabilities of treatment success for
different tumor sizes with different combinations of mutations. In
the body of the table, we present two probabilities corresponding
to the two extreme values of the drug-induced killing rate, see
inequality (7) of Text S1: the 1
st value in each cell corresponds to
taking the maximum of the killing rates and the 2
nd one
corresponds to taking the sum of the killing rates. We can see
that switching partially-resistant mutations on and off only changes
the probabilities by less than 0.1%.
Using the basic model with all types of mutations on, and
varying the number of triply-resistant mutations, i123,w e
calculated the probability of treatment success for different tumor
loads, see table 4. Increasing the number of triply-resistant
mutants, i123, causes a significant decrease in the probability of
treatment success. We conclude that the number of fully cross-
resistant mutants dramatically affects the probability of treatment
success. This implies that as long as there is at least one fully cross-
resistant mutant, the success rate of a treatment solely depends on
the number of these mutants, regardless of how many drugs are
involved.
An analytical justification of these findings comes from an
expansion, in terms of the small mutation rate, u, of the probability
of treatment failure. In long-term drug combination treatments,
the reason for treatment failure is assumed to be the creation of
fully resistant mutants. The expected number of such mutants at
the start of treatment (which is a deterministic quantity) correlates
with the probability of treatment failure. Let us write down the
system of deterministic equations governing the dynamics of all
resistance classes; for illustration purposes we do this for the case of
Table 3. Probability of treatment success for a three drug combination treatment with different mutations ‘‘on’’ and ‘‘off’’.
Log10N
Triply resistant
mutations only
Doubly- and triply-resistant
mutations
Singly- and triply-resistant
mutations All mutations
4.8 0.99930112
0.99934929
0.99930095
0.99934912
0.99930112
0.99934929
0.99930070
0.99934887
5.9 0.99112253
0.99172971
0.99111991
0.99172708
0.99112253
0.99172970
0.99111603
0.99172331
7.0 0.89709172
0.90350403
0.89706178
0.90347364
0.89709172
0.90350401
0.89701783
0.90343032
8.1 0.40499863
0.42232880
0.40491946
0.42224265
0.40499862
0.42232872
0.40480337
0.42211996
9.2 0.05046559
0.05400193
0.05044983
0.05398387
0.05046559
0.05400191
0.05042673
0.05395817
10.3 0.00413271
0.00443748
0.00413136
0.00443592
0.00413271
0.00443748
0.00412937
0.00443370
11.4 0.00032392
0.00034791
0.00032382
0.00034779
0.00032392
0.00034791
0.00032366
0.00034761
We take as parameters L~1, d~0, hk~10, u~10{8, i0~1, i123~1, i1~i2~i3~30, i12~i13~i23~20 (for detailed definitions of the parameters see Text S1). For each
tumor size and specific mutation gates we have two probabilities: the 1
st one corresponds to fm h1,...,hm ðÞ ~Max hi ðÞ , and the second one to fm h1,...,hm ðÞ ~
P m
i~1
hi.
doi:10.1371/journal.pone.0012300.t003
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_ x x00~ L00 1{u1{u2{u12 ðÞ {D00 ½  x00,
_ x x10~L00u1x00z L10 1{u2{u12 ðÞ {D10 ½  x10,
_ x x01~L00u2x00z L01 1{u1{u12 ðÞ {D01 ½  x01,
_ x x11~L00u12x00zL10 u2zu12 ðÞ x10zL01 u1zu12 ðÞ x01z L11{D11 ½  x11,
ð2Þ
where variables xs indicate the average numbers of mutants of
resistance class s, Ls and Ds are the corresponding division and
death rates, and the initial condition isw
x00 0 ðÞ ~M0, x10 0 ðÞ ~x01 0 ðÞ ~x11 0 ðÞ ~0:
This system was derived by using standard methods from the
stochastic master equation, see text S1. We are interested in
the solution in the lowest order in u, therefore in the parentheses
the mutation rates can be neglected compared to 1:
_ x x00~ L00{D00 ½  x00,
_ x x10~L00u1x00z L10{D10 ½  x10,
_ x x01~L00u2x00z L01{D01 ½  x01,
_ x x11~L00u12x00zL10 u2zu12 ðÞ x10zL01 u1zu12 ðÞ x01z L11{D11 ½  x11:
We can see that the quantity x00 (fully-susceptible cells) is
independent of the mutation rate. Quantities x10 and x01 (one-hit
mutants), in the leading order, are proportional to the first power
on u. Finally, the quantity x11 (fully-resistant mutants) in the
leading order is proportional to the quantity i12u, the rate of
creation of doubly-resistant mutants directly from fully-susceptible
mutants. In the absence of cross-resistance (i12~0), the expected
number of fully-resistant mutants is proportional toi1i2u2.
Similarly, for three-drug treatments, the leading term in the
expansion for the number of triply-resistant cells, x111,i s
proportional to i123u. In the absence of triply-resistant mutants
(that is, if i123~0), this quantity’s largest contribution is quadratic
in u and proportional to
i1i23zi2i13zi3i12zi12i13zi13i23zi23i12 ðÞ u2: ð3Þ
Clearly, fully cross-resistant mutations comprise the dominant
influence on the expressions for treatment failure (i12 for 2-drug
treatments and i123 for 3-drug treatments); notice that the leading
term in the expansion of the probability of treatment failure only
has these mutations. Therefore, we can conclude that only these
highest fully-cross-resistant mutations should be taken into account
when evaluating the chances of treatment success for different
drug combinations. This gives rise to some fairly straightforward
algorithms which allow us to single out the most efficient treatment
protocols. They are described in the next sections.
Algorithm A1 for finding the best treatments in the case
where there is at least one fully cross-resistant mutant
We will now develop an algorithm which allows us to identify
the best possible treatments without the use of stochastic
calculations. Our goal is to maximize the probability of treatment
success, while minimizing the number and concentration of drugs.
In the case where there are triply-resistant mutations, the
number of mutations that confer resistance to all the drugs in the
treatment is of most importance in determining the best treatment
strategy. Therefore, we only need to inspect tables 1, 2.1–2.4 and
3.1–3.8 of Text S1 for the best treatment strategies. The main idea
is as follows. From all possible treatments, we need to identify the
ones with the smallest number of fully cross-resistant mutants.
Among these treatments, choose the ones that contain the smallest
number of drugs at the lowest concentrations. More precisely,
among treatments containing the same sets of drugs, we pick only
the ones with the lowest concentrations, and if a particular
treatment uses a subset of the drugs (at the same concentrations) of
another treatment, we only include the treatment with the smaller
number of drugs. The following algorithm (which we call
Algorithm A1) executes this program and produces a set of the
best possible treatments:
1) Identify all treatments that have the least number of fully
cross-resistant mutants and list them, B~ Tj
   n
j~1. That is,
all treatments in B will have the same number of fully cross-
resistant mutants.
2) Divide B into three disjoint subsets: B~B1|B2|B3, where
Bk consists of treatments with k drugs. If the number of fully
cross-resistant mutations is zero, stop and continue with
Algorithm A2 in the next section. Otherwise, continue to
step 3.
3) Note that B1 consists of one-drug treatments, each with a
specific concentration. If a particular drug appears more
than once in B1 with different concentrations, then only
keep the one with the lowest concentration, so that we have
a refined set ~ B B1(B1.
4) If a drug with its particular concentration that is in the set B1
appears in B2 or B3, then do not consider those treatments.
This will produce the first refinement of the sets B’2(B2
andB’3(B3.
5) If a pair of treatments in B’2 has the same two drugs and one
of the drugs has the same concentration in the pair, then get
rid of the treatment whose other drug is of a higher
concentration. This will fully refine the set ~ B B2(B’2(B2.
6) If two of the drugs with specific concentrations in B’3 appear
in B2, then get rid of it so to refine the set B’’3(B’3.
7) Next, if a pair of treatments in B’’3 has the same three drugs,
and the concentration of one or more drugs is higher in one
treatment than in the other, then keep the treatment with
the drug(s) of lower concentration. This will produce a fully
refined set ~ B B3(B’’3(B’3(B3.
Table 4. Probability of treatment success for a three drug
combination treatment with different number of
triply-resistant mutations.
Log10N-. 4.8 5.9 7.0 8.1 9.2 10.3 11.4
i123=0 1.000 1.000 0.9999 0.9988 0.9851 0.8376 0.2871
i123=1 0.9993 0.9911 0.8970 0.4048 0.0504 0.0041 0.0003
i123=2 0.9986 0.9824 0.8133 0.2538 0.0259 0.0021 0.0002
i123=3 0.9979 0.9738 0.7439 0.1849 0.0174 0.0014 0.0001
i123=4 0.9972 0.9654 0.6854 0.1454 0.0131 0.0010 0.0001
We take as parameters L~1, d~0, hk~10, u~10{8, i1~i2~i3~30,
i12~i13~i23~20,a n dfm h1,...,hm ðÞ ~Max hi ðÞ (for detailed definitions of the
parameters see Text S1).
doi:10.1371/journal.pone.0012300.t004
ð2Þ
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strategies.
For illustration, we will go through steps 1–8 of Algorithm A1 to
identify the set of the best treatments possible with the three
available inhibitors, imatinib, nilotinib, and dasatinib. Let us
denote by
TI C1,NC2,DC3
  
the treatment with imatinib (I), nilotinib (N), and dasatinib (D).
The subscripts, Ci, meaning concentration, will have four values: 0
for none, L for low, M for medium, and H for high. Thus,
TI 0,NM,DM ðÞ , represents treating with twodrugs, nilotinib and
dasatinib, both at medium concentrations.
We first note that any treatment with only one fully cross-
resistant mutation is in the set B. We will turn our attention to B1.
This set consists of T(I0,NH,D0) and TI 0,N0,DH ðÞ , and is
already fully refined, so that
~ B B1~ TI 0,NH,D0 ðÞ ,TI 0,N0,DH ðÞ fg :
We next obtain the sets B’2 and B’3 by getting rid of any two or
three drug treatments that have either nilotinib or dasatinib at
high concentrations:
B’2~ TI 0,NL,DM ðÞ ,TI 0,NM,DM ðÞ fg ,
B’3~ TI H,NL,DM ðÞ ,TI H,NM,DL ðÞ ,TI L,NL,DM ðÞ ,TI L,NM,DM ðÞ , f
TI M,NL,DM ðÞ ,TI M,NM,DM ðÞ ,TI H,NM,DM ðÞ g :
This completes steps 1–4. Now for step 5, we can refine B’2 by
noticing that both treatments have dasatinib at medium and
nilotinib at low and medium. Thus, we have the fully refined set
~ B B2~ TI 0,NL,DM ðÞ fg :
Next, we use ~ B B2 to refine B’3:
B’’3~ TI H,NM,DL ðÞ fg :
This set cannot be further refined and thus,
~ B B3~ TI H,NM,DL ðÞ fg :
Thus, we have the following set of the best treatment strategies
with imatinib, nilotinib, and dasatinib:
~ B B~ TI 0,NH,D0 ðÞ ,TI 0,N0,DH ðÞ ,T(I0,NL,DM),TI H,NM,DL ðÞ fg :
In words, the best treatments are as follows:
N 1 drug treatment with nilotinib at a high concentration.
N 1 drug treatment with dasatinib at a high concentration.
N 2 drug combination treatment with nilotinib at a low
concentration and dasatinib at a medium concentration.
N 3 drug combination treatment with imatinib at a high
concentration, nilotinib at a medium concentration, and
dasatinib at a low concentration.
Since all these treatment protocols have a fully cross-resistant
mutant, T315I, they all have similar probabilities. It will be the
physician’s decision influenced by the patient’s needs that will
determine exactly which treatment to use.
Next, we would like to consider incorporating the inhibitor
SGX70393 in a combination treatment with at most three drugs.
Algorithm A2 for finding the best treatments in the case
where there are no fully cross-resistant mutants
If it is possible to use drugs which do not possess a possibility of
triply-resistant mutations, this makes the probability of treatment
success much higher. In this case, Algorithm A1 will not work, and
treatment protocol optimization requires an alternative counting
algorithm. This algorithm, which we call Algorithm A2, is
developed in this section.
We first define two numbers as follows: for two drugs,
S 2 ðÞ ~i1i2,
and for three drugs,
S 3 ðÞ ~i1i23zi2i13zi3i12zi12i13zi13i23zi23i12:
These choices are dictated by our theoretical considerations,
see expression (3). It turns out that the quantities S(2) or S(3) (for
two- and three-drug treatments respectively) play a very important
role in the ordering of various combination treatments. They
indicate the main contribution to the probability of treatment
failure (for two-drug and three-drug treatments respectively) due to
resistant mutations. The smaller the S(2) or S(3) index, the larger is
the probability of treatment success. In what follows we will show
that the indices S(2) and S(3) provide a convenient ordering of
drug combinations equivalent to ordering in terms of their
probability of treatment success.
To demonstrate this, we calculated the probabilities of
treatment success using several different parameters, and we
found that an increase in S(2) or S(3) results in a decrease in the
probability of treatment success, such that the numbers S(2) and
S(3) give an ordering of probabilities for any tumor load. In figure 2
we present the calculated probabilities of treatment success, for
tumor load of size N~1010, for different parameter values, for
two-drug (solid markers) and three-drug (empty markers) treat-
ments, as functions of the numbers S(2) and S(3) (see also tables 5
and 6).
From this result, we construct an algorithm (Algorithm A2) for
the case where there are no fully cross-resistant mutants. This
algorithm will narrow down the sets B2 and B3 obtained from step
2 of Algorithm A1, to an ordered set, which starts with the
treatment with the highest probability of success and lists the
treatments in decreasing order; this set is also refined of treatments
that have higher concentrations or more drugs involved than ones
which produce the same probabilities. Here is the main idea of the
algorithm. If there are treatments characterized by the absence of
fully cross-resistant mutations, we arrange those treatments
according to their indices S(2) and S(3). Within each subgroup
(with a given index value), perform refinements identical to those
of Algorithm A1. As a result, we obtain an ordered set of
treatments which differ by their probability of treatment success.
Below are the steps of Algorithm A2:
1) Suppose there are ~ l l many treatments in set B2 and the
numbers S(2) k ðÞfor the k
th treatments in B2 take the
following distinct values: m 1 ðÞ wm 2 ðÞ w...wml ðÞ , where
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these numbers as follows: B2~A2
m(1)|   |A2
m(l).
2) Suppose there are ~ q q many treatments in set B3 and the
numbers S(3) k ðÞ for the k
th treatments in B3 take exactly q
distinct values, p 1 ðÞ wp 2 ðÞ w...wpq ðÞ , where qƒ~ q q. From
this, we can partition the set B3 according to these numbers
as follows: B3~A3
p(1)|   |A3
p(q).
3) We proceed to refine within each subset, A2
m(k) and A3
p(k).F o r
the subset A2
m(1) we identify all the sets A3
p(k), where
m 1 ðÞ ƒpk ðÞ , and perform steps 3–7 of Algorithm A1. Next
for subset A2
m(2) we identify all the sets A3
p(k),s u c ht h a t
m 2 ðÞ ƒpk ðÞ vm 1 ðÞ , and perform steps 3–7 of Algorithm A1.
Continue this process for all mk ðÞ , 1ƒkƒl.T h i sw i l lf u l l y
refine eachsubset of B2 and B3; denote the newrefined sets by
~ A A2~~ A A2
m(1)|   |~ A A2
m(a) and ~ A A3~~ A A3
p(1)|   |~ A A3
p(b):
4) Suppose we order all possible numbers S(2) and S(3) for the
treatments in the sets ~ A A2 and ~ A A3, respectively, in increasing
order: w 1 ðÞ ,w 2 ðÞ ,   ,wv ðÞ . Then order all subsets ~ A A2
m(k) and
~ A A3
p(k) according to w 1 ðÞ ,w 2 ðÞ ,   ,wv ðÞ , using the conven-
tion that if S(2)~S(3)~wk ðÞ , then we place ~ A A2
w(k) before
~ A A3
w(k). This will produce an ordered set, ~ A A, of the best
treatments in sets B2 and B3, starting with the treatment
with the highest probability of success.
The set ~ A A is an ordered set. A physician should consider the first
treatment on the list; if the patient cannot tolerate that treatment,
then the next treatment in the list should be considered, and so on.
Note that this is different from the set ~ B B, obtained from Algorithm
A1. In set ~ B B, all treatments have the same success rate, give or take
a percent. This is not true with the resulting set, ~ A A, of Algorithm
A2; there, the probabilities of treatment success can have a large
range.
We will apply the new algorithm to obtain the best treatment
strategies with the inclusion of the inhibitor SGX70393. Although
the inhibitor SGX70393 is not available for use, it is a good
example of a drug with no fully cross-resistant mutants if it is
combined with any of the existing inhibitors.
We begin by identifying the sets B2 and B3 using step 1 of
Algorithm A1. This produces 45 three-drug treatments and 7 two-
drug treatments. After steps 3 and 4 of the algorithm we have
tables 5 and 6 for the sets A2 and A3, respectively. Notice that we
also provide a probability of treatment success for several cases to
show how well the numbers S(2) and S(3) work in ordering the
probabilities.
We proceed to step 5 by ordering the numbers S(2) in
decreasing order: 29, 24, 20, and 6 (m 1 ðÞ , m 2 ðÞ , m 3 ðÞ , and m 4 ðÞ ).
For m 1 ðÞ ~29, we perform steps 3–7 of Algorithm A1 on rows 6
and 7 of table 5 and rows 29–45 of table 6 which correspond to
p 1 ðÞ ~29, 31, 38, 43, 47, 58, 75, 85§29~m 1 ðÞ . This step results
in removing rows 29–38 of table 6, because they contain
treatments which utilize the same drugs at the same concentrations
as the treatments in rows 6 and 7 of table 5, together with
additional drugs. This makes these treatments redundant.
For m 2 ðÞ ~24, steps 3–7 of Algorithm A1 have to be performed
on row 5 of table 5 and row 28 of table 6 which correspond to
Figure 2. The probability of treatment success as a function of
the numbers S(2) and S(3). Different markers correspond to different
treatment parameters: circles (division rate L=10, death rate d=9,
drug-induced death rate hi=10, mutation rate u=10
27, cancerous
population size at the start of treatment N=10
10), squares
(L~1,d~0,hi~10,u~10{8,N~1011), diamonds (L~5,d~4,hi~10,
u~10{8,N~1012), triangles (L~5,d~4,hi~10,u~10{8,N~1013).
Empty markers denote three-drug treatments, and solid ones – two-
drug treatments. The data are presented in tables 5 and 6.
doi:10.1371/journal.pone.0012300.g002
Table 5. Set B2 after step 3 of Algorithm A2.
Concentrations of the drugs in the
following order: Ima, Nilo, Dasa, SGX S
(2)
L=10, d=9, hi=10,
u=10
27,N=1 0
10
L=1, d=0, hi=10,
u=10
28,N=1 0
11
L=5, d=4, hi=10,
u=10
28,N=1 0
12
L=5, d=4, hi=10,
u=10
28,N=1 0
13
1 0, H, 0, H 6 0.3930 0.9985 0.7240 0.2075
2 0, 0, H, H 6 0.3930 0.9985 0.7240 0.2075
3 0, H, 0, M 20 0.1690 0.9947 0.4285 0.0700
4 0, 0, H, M 20 0.1690 0.9947 0.4285 0.0700
5 H, 0, 0, H 24 0.1460 0.9940 0.3830 0.0585
6 0, H, 0, L 29 0.1250 0.9922 0.3380 0.0485
7 0, 0, H, L 29 0.1250 0.9922 0.3380 0.0485
The second column shows the concentrations of each drug in order of imatinib (ima), nilotinib (nilo), dasatinib (dasa), and SGX70393 (SGX). The last 4 columns show the
probability of treatment success given the parameters shown taking the sum of killing rates. For detailed definitions of the parameters see Text S1.
doi:10.1371/journal.pone.0012300.t005
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Concentrations of the drugs in the
following order: Ima, Nilo, Dasa, SGX S
(3)
L=10, d=9, hi=10,
u=10
27,N=1 0
10
L=1, d=0, hi=10,
u=10
28,N=1 0
11
L=5, d=4, hi=10,
u=10
28,N=1 0
12
L=5, d=4, hi=10,
u=10
28,N=1 0
13
1 0, H, L, H 6 0.3980 0.9986 0.7400 0.2215
2 L, H, 0, H 6 0.4020 0.9985 0.7240 0.2205
3 L, 0, H, H 6 0.4020 0.9985 0.7240 0.2205
4 0, L, H, H 6 0.4030 0.9986 0.7410 0.2225
5 M, H, 0, H 6 0.4020 0.9986 0.7390 0.2205
6 M, 0, H, H 6 0.4020 0.9986 0.7390 0.2205
7 0, M, H, H 6 0.4030 0.9986 0.7275 0.2110
8 0, H, M, H 6 0.4030 0.9986 0.7285 0.2115
9 H, H, 0, H 6 0.4040 0.9986 0.7295 0.2125
10 H, 0, H, H 6 0.4040 0.9986 0.7295 0.2125
11 0, H, H, H 6 0.4040 0.9985 0.7295 0.2125
12 H, 0, M, H 14 0.2280 0.9966 0.5410 0.1055
13 H, M, 0, H 16 0.2050 0.9961 0.4890 0.0875
14 0, M, M, H 19 0.1800 0.9950 0.4440 0.0740
15 0, H, M, M 20 0.1740 0.9948 0.4340 0.0710
16 M, H, 0, M 20 0.1750 0.9947 0.4320 0.0705
17 M, 0, H, M 20 0.1750 0.9947 0.4320 0.0705
18 0, M, H, M 20 0.1760 0.9948 0.4350 0.0715
19 H, H, 0, M 20 0.1760 0.9948 0.4350 0.0715
20 H, 0, H, M 20 0.1760 0.9948 0.4350 0.0715
21 0, H, H, M 20 0.1760 0.9948 0.4360 0.0715
22 0, H, L, M 20 0.1730 0.9948 0.4325 0.0710
23 L, H, 0, M 20 0.1750 0.9947 0.4310 0.0705
24 L, 0, H, M 20 0.1750 0.9947 0.4310 0.0705
25 0, L, H, M 20 0.1760 0.9948 0.4340 0.0710
26 H, L, 0, H 21 0.1660 0.9945 0.4190 0.0675
27 H, 0, L, H 22 0.1590 0.9942 0.4070 0.0640
28 0, H, H, L 28 0.1340 0.9927 0.3530 0.0520
29 H, H, 0, L 29 0.1300 0.9924 0.3440 0.0500
30 H, 0, H, L 29 0.1300 0.9924 0.3440 0.0500
31 0, H, M, L 29 0.1290 0.9923 0.3435 0.0500
32 M, H, 0, L 29 0.1300 0.9923 0.3425 0.0495
33 M, 0, H, L 29 0.1300 0.9923 0.3425 0.0495
34 0, M, H, L 29 0.1300 0.9924 0.3440 0.0500
35 L, H, 0, L 29 0.1300 0.9923 0.3410 0.0490
36 L, 0, H, L 29 0.1300 0.9923 0.3410 0.0490
37 0, L, H, L 29 0.1300 0.9924 0.3435 0.0495
38 0, H, L, L 29 0.1290 0.9923 0.3425 0.0495
39 0, L, M, H 31 0.1200 0.9922 0.3380 0.0485
40 0, M, M, M 38 0.1010 0.9897 0.2795 0.0375
41 M, 0, M, H 43 0.0920 0.9891 0.2555 0.0330
42 0, M, M, L 47 0.0840 0.9872 0.2380 0.0305
43 L, 0, M, H 58 0.0700 0.9851 0.2010 0.0245
44 0, L, M, M 75 0.0550 0.9794 0.1620 0.0190
45 0, L, M, L 85 0.0490 0.9766 0.1455 0.0165
doi:10.1371/journal.pone.0012300.t006
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further refinement.
For m 3 ðÞ ~20, we perform steps 3–7 of Algorithm A1 on the
rows 3 and 4 of table 5 and rows 15–27 of table 6 which
correspond to m 3 ðÞ ~20ƒ20, 21, 22v24~m 2 ðÞ . This step
results in removing rows 15–25 of table 6.
Finally, for m 4 ðÞ ~6, we perform steps 3–7 of Algorithm A1 on
the rows 1 and 2 of table 5 and rows 1–14 of table 6 which
correspond to m 4 ðÞ ~6ƒ6, 14, 16, 19v20~m 3 ðÞ . This step
results in removing rows 1–12 of table 6.
We now order the remaining treatments according to step 7 and
produce table 7.
Algorithm A2 allowed us to narrow down the 57 treatments of
step 2 to just 20 treatments. These 20 treatments are in order of
decreasing probability of treatment success. They are presented in
figure 3, as a plot of the probability of treatment success as a
function of different treatment protocols. As we can see, all the
best treatment protocols rely on the usage of the T315I inhibitor.
Furthermore, the treatments corresponding to the highest success
probabilities are two-drug treatments where both drugs are used at
the highest concentrations. These are followed by three-drug
treatments with drugs used at lower concentrations.
Discussion
We have developed a counting method to narrow down all
possible treatments to the best ones. Although the development of
the methodology relies on stochastic calculations, this counting
method can be used by biologists and physicians, and does not
require a strong mathematical background. To implement the
method, one does not need to calculate the specific probabilities
for each treatment, but simply follow the steps to select and order
different protocols. Along with the counting scheme, which
accounts for the hierarchy of probabilities of success, we weed
out many treatments to minimize the number of drugs in
combination and their respective concentrations.
To create this method we used the data from biological
experiments to identify which types of point mutations can cause
resistance to various drugs at different concentrations. In general,
Table 7. Set ~ A A after all the steps of Algorithm A2. Details are as in table 5.
Concentrations of the drugs in the
following order: Ima, Nilo, dasa, SGX S
(k)
L=10, d=9, hi=10,
u=10
27,N=1 0
10
L=1, d=0, hi=10,
u=10
28,N=1 0
11
L=5, d=4, hi=10,
u=10
28,N=1 0
12
L=5, d=4, hi=10,
u=10
28,N=1 0
13
1 0, H, 0, H 6 0.3930 0.9985 0.7240 0.2075
2 0, 0, H, H 6 0.3930 0.9985 0.7240 0.2075
3 H, 0, M, H 14 0.2280 0.9966 0.5410 0.1055
4 H, M, 0, H 16 0.2050 0.9961 0.4890 0.0875
5 0, M, M, H 19 0.1800 0.9950 0.4440 0.0740
6 0, H, 0, M 20 0.1690 0.9947 0.4285 0.0700
7 0, 0, H, M 20 0.1690 0.9947 0.4285 0.0700
8 H, L, 0, H 21 0.1660 0.9945 0.4190 0.0675
9 H, 0, L, H 22 0.1590 0.9942 0.4070 0.0640
10 H, 0, 0, H 24 0.1460 0.9940 0.3830 0.0585
11 0, H, H, L 28 0.1340 0.9927 0.3530 0.0520
12 0, H, 0, L 29 0.1250 0.9922 0.3380 0.0485
13 0, 0, H, L 29 0.1250 0.9922 0.3380 0.0485
14 0, L, M, H 31 0.1200 0.9922 0.3380 0.0485
15 0, M, M, M 38 0.1010 0.9897 0.2795 0.0375
16 M, 0, M, H 43 0.0920 0.9891 0.2555 0.0330
17 0, M, M, L 47 0.0840 0.9872 0.2380 0.0305
18 L, 0, M, H 58 0.0700 0.9851 0.2010 0.0245
19 0, L, M, M 75 0.0550 0.9794 0.1620 0.0190
20 0, L, M, L 85 0.0490 0.9766 0.1455 0.0165
doi:10.1371/journal.pone.0012300.t007
Figure 3. The ordered set of the best treatment protocols
resulting from a application of Algorithm A2. The probability of
treatment success is plotted as a function of treatment protocols, see
also table 7. The parameters are as in figure 2.
doi:10.1371/journal.pone.0012300.g003
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mutations into three classes, singly-, doubly-, and triply-resistant
mutations, depending on how many different drugs (out of the
three drugs in the combination) they confer resistance to. From the
experimental data, we count the numbers of mutations of each
type, for each possible treatment. From this information, we
provide two algorithms: one that deals with treatments that do not
possess any triply-resistant mutants (Algorithm A2), and another
one for treatments which include only drugs with a possibility of
triply-resistant mutations (Algorithm A1).
The mathematics that we used to develop these methods
included a stochastic model of resistance [59,60] refined to allow
for different drug concentrations. We used analysis on this model
along with numerical results to support the proposed counting
techniques. One important pattern that we found is that in the
presence of a possibility of triply-resistant mutations, other types of
mutations (such as doubly-and singly-resistant mutations) do not
make a noticeable difference in the probability of treatment
success. This result suggests that in choosing the optimal
combination treatment, one should look for drugs with the
smallest number of fully cross-resistant mutants. If for a three-drug
therapy, a triply-resistant mutant exists (which is the case with
imatinib, dasatinib and nilotinib), then the presence of other
mutations (which may change depending on the dosage of the
drugs) does not make a difference for the probability of the
treatment success. Therefore, one should use the lowest possible
doses (and the smallest number of drugs) as long as there is only
one fully-cross-resistant mutant present (note that lowering the
doses too much would lead to a possibility of more than one triply-
resistant mutants). This result is not in contradiction with the
recent work of [66], where it is suggested that once imatinib-based
therapy failed, it is possible to find out what mutants caused
resistance, and then choose the best second-line drug based on
this. The knowledge of the mutations in an individual patient will
of course help refine the treatment strategy. Our approach only
gives a suggestion about the best plan of action before we know
anything about the mutations in an individual patient.
The algorithms of treatment optimization developed here have
the advantage that they do not require any information on the
(usually unknown) parameters which are part of traditional
stochastic modeling. We do not need to know the tumor size,
the mutation rates, the growth/death/quiescence rates of cancer
cells, or the killing rates of individual drugs or drugs in
combination. The only information which is required to execute
the algorithm is the activity spectra of the drugs in use. These are
comprised of data on the numbers and resistance properties of
mutants resistant to each of the drugs. We hope that this technique
will aid physicians in the choice of the best possible combination
therapies with current and future, undeveloped inhibitors, which
maximize treatment success and minimize the harm that a patient
may endure from side effects of such drugs.
In this study, we illustrated the usage of the algorithms with the
data from [1,2]. The method developed here is rather general and
can be applied to other data sets. An example of a recently built
data set which includes mutations in the context of imatinib,
dasatinib, nilotinib and a newer drug bosutinib, can be found in
[67]. A very promising new drug which shows activity against
T315I-mutants is danusertib, whose properties are now being
studied [31,34,35,68]. Once more information is available on the
activity spectrum of this drug, one will be able to use Algorithm A2
in treatment designs involving danusertib together with some of
the older generation inhibitors. In this case, no triply-resistant
mutants exist, and one can come up with a hierarchy of
combination protocols based on the doubly- and singly-resistant
mutations.
In the present study we concentrated on combination
treatments. Although the common present clinical practice is to
treat patients with one drug (usually imatinib) and if resistance
arises, switch to a different drug, it has been suggested that a more
efficient treatment strategy is to combine several drugs [1,12,27].
Combination protocols have the advantage of minimizing the
chance of treatment failure due to drug resistance generation. It
can be shown by means of mathematical modeling that cyclic
therapies (which consist of cycles of single-drug applications) are
not nearly as efficient as combination therapies at achieving the
maximum treatment success. These considerations provided
motivation for optimizing combination protocols on the basis of
cross-resistance and drug concentration data. A similar analysis of
cyclic therapies, and also of informed therapies where certain
aspects of individual patient mutation spectrum are known, is a
subject of current and future research.
Finally, a very desirable future extension of the present study
would be to apply the algorithm to in vivo data when those become
available. For that more clinical trials must be conducted with
combination treatments consisting of imatinib, nilotinib, dasatinib
and any other drugs that are developed, at different levels of
concentration.
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